| NCT03899155 | Pan Tumor Rollover Study | recruiting | Phase 2 | 1,500 | Bristol-Myers SquibbINDUSTRY | 38 | Sep 23, 2026 | clinicaltrials |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | recruiting | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Sep 23, 2026 | clinicaltrials |
| NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in India | not yet recruiting | Phase 4 | 30 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT02693535 | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer(TAPUR) | recruiting | Phase 2 | 4,200 | American Society of Clinical OncologyOTHER | 2 | Sep 22, 2026 | clinicaltrials |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | active not recruiting | Phase 1 | 190 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT04302025 | A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)(NAUTIKA1) | recruiting | Phase 2 | 99 | Genentech, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT01708954 | Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer(CANOPY) | active not recruiting | Phase 2 | 47 | Rana McKay, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06862869 | Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy | recruiting | — | 800 | Hoffmann-La RocheINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04589845 | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | active not recruiting | Phase 2 | 920 | Hoffmann-La RocheINDUSTRY | 23 | Sep 4, 2026 | clinicaltrials |
| NCT03178552 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST) | active not recruiting | Phase 2 / Phase 3 | 1,000 | Hoffmann-La RocheINDUSTRY | 27 | Sep 3, 2026 | clinicaltrials |
| NCT05536141 | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors(ARC-20) | recruiting | Phase 1 | 362 | Arcus Biosciences, Inc.INDUSTRY | 4 | Aug 31, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06428396 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | active not recruiting | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Aug 28, 2026 | clinicaltrials |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC(ALKAZAR) | recruiting | Phase 3 | 450 | Nuvalent Inc.INDUSTRY | 29 | Aug 25, 2026 | clinicaltrials |
| NCT06382948 | Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.(ADELA) | recruiting | Phase 3 | 300 | MedSIROTHER | 9 | Aug 24, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 4 | 12 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04280081 | A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation(LIBRETTO-321) | active not recruiting | Phase 2 | 77 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05170204 | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)(HORIZON 1) | active not recruiting | Phase 3 | 68 | Hoffmann-La RocheINDUSTRY | 19 | Aug 5, 2026 | clinicaltrials |
| NCT01639508 | Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | recruiting | Phase 2 | 86 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03914300 | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | active not recruiting | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05663710 | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC | recruiting | Phase 1 / Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study(IMbrella B) | active not recruiting | Phase 3 | 1,000 | Hoffmann-La RocheINDUSTRY | 24 | Jul 24, 2026 | clinicaltrials |
| NCT01087554 | Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | active not recruiting | Phase 1 | 249 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05722886 | DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol(DETERMINE) | recruiting | Phase 2 / Phase 3 | 825 | Cancer Research UKOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03032406 | CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer | active not recruiting | Phase 2 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04188548 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer(EMBER) | active not recruiting | Phase 1 | 379 | Eli Lilly and CompanyINDUSTRY | 8 | Jun 22, 2026 | clinicaltrials |
| NCT05525858 | KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II(KOSMOSII) | recruiting | — | 1,000 | Seoul National University Bundang HospitalOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05573126 | Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | recruiting | Phase 1 / Phase 2 | 95 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer(ELEVATE) | active not recruiting | Phase 1 / Phase 2 | 435 | Stemline Therapeutics, Inc.INDUSTRY | 13 | Jun 12, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT04759911 | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 64 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03202940 | A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | active not recruiting | Phase 1 / Phase 2 | 16 | Massachusetts General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07062965 | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | recruiting | Phase 3 | 400 | PfizerINDUSTRY | 27 | May 6, 2026 | clinicaltrials |
| NCT01187199 | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | active not recruiting | Phase 1 | 278 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT05987644 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements(DURABLE) | recruiting | Phase 1 / Phase 2 | 56 | Joshua PalmerOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03377023 | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 66 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04963283 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | active not recruiting | Phase 2 | 48 | University of Colorado, DenverOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)(CAPTUR) | recruiting | Phase 2 | 720 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04268550 | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) | active not recruiting | Phase 2 | 124 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531) | active not recruiting | Phase 3 | 291 | Loxo Oncology, Inc.INDUSTRY | 20 | Mar 19, 2026 | clinicaltrials |
| NCT04819100 | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)(LIBRETTO-432) | active not recruiting | Phase 3 | 152 | Eli Lilly and CompanyINDUSTRY | 32 | Mar 4, 2026 | clinicaltrials |
| NCT07435584 | Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)(EVER-RECODE) | not yet recruiting | Phase 1 / Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07418879 | A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC | not yet recruiting | N/A | 25 | Fudan UniversityOTHER | 0 | Feb 18, 2026 | clinicaltrials |